WO2014015507A1

WO2014015507A1 - Application of shengui capsule in preparing antithrombotic drugs

Info

Publication number: WO2014015507A1
Application number: PCT/CN2012/079235
Authority: WO
Inventors: 朱飞进
Original assignee: 上海玉丹药业有限公司; 玉丹（加拿大）医药公司
Priority date: 2012-07-24
Filing date: 2012-07-27
Publication date: 2014-01-30
Also published as: CN102846711A; CN102846711B

Abstract

An application of Shengui capsule in preparing antithrombotic drugs. The Shengui capsule is prepared by using such traditional Chinese medicines as red ginseng, ligusticum wallichii, and cassia twig.

Description

Application of Shenui Capsule in Preparation of Antithrombotic Drugs

Technical field:

The invention relates to a new use of a medicine, in particular to a medicine preparation prepared by the traditional Chinese medicine red ginseng, Chuanxiong and Guizhi, in the preparation of an antithrombotic medicament.

Background Art:

Pharmaceutical preparations such as capsule preparations prepared with traditional Chinese medicine red ginseng, Chuanxiong and Guizhi have been marketed, called: Shenui Capsule, whose main functions are: Yiqi Tongyang, promoting blood circulation and removing blood stasis. For the lack of heart, qi deficiency and blood stasis syndrome. Symptoms: Chest pain, fixed, late at night, aggravated by cold, or chilly, warm, faceless; coronary heart disease, angina see the above syndrome. Book

Pharmacological studies have shown that: Shengui Capsule has protective effect on myocardial infarction induced by coronary artery ligation and myocardial ischemia induced by vasopressin in rats; it can increase coronary flow, slow heart rate and reduce myocardial consumption The amount of oxygen reduces the peripheral resistance.

The preparation method of Shenui Capsule is as follows:

Ingredients: Red Ginseng, Chuanxiong, Guizhi

The above three flavors, take red ginseng, pulverize into fine powder, spare; the remaining red ginseng is pulverized into coarse powder, and the percolation method under the extract of extract and extract (Chinese Pharmacopoeia 2000 edition, Appendix I 0), with ethanol Solvent for percolation, collecting percolate, standby; Chuanxiong, Guizhi plus water distillation to extract volatile oil, collect volatile oil, spare; distillate filtered, filtrate for use; medicinal residue and red ginseng residue simmered twice with water, filter The filtrate is combined, concentrated, allowed to cool, added with ethanol, placed, filtered, and the filtrate is combined with the red ginseng osmosis solution, and the ethanol is recovered and concentrated to a thick paste. The red ginseng powder is added, the hook is mixed, dried, and pulverized into fine powder. The volatile oil is absorbed by the remaining red ginseng powder, mixed with the hook, and then mixed with the above-mentioned fine powder, added with appropriate amount of starch, mixed with hooks, filled into capsules, and made into granules, which is obtained.

In the heart or vascular lumen of a living body, the process of coagulation of blood or the formation of solid particles in the blood to form a solid mass, called thrombosis, a solid mass formed in the process. It is called thrombus (thrombus). Under physiological conditions, blood clotting factors are constantly activated, producing thrombin, forming microfibrin, which is deposited on the intima of the blood vessels, but these traces of fibrin are constantly activated by the fibrinolytic system. Dissolved, while activated clotting factors are constantly The ground is engulfed by the mononuclear phagocytic system. The dynamic balance of the above coagulation system and fibrinolytic system sometimes breaks the dynamic balance under certain factors that promote the blood coagulation process, triggers the coagulation process, and forms a thrombus.

Thrombosis not only has a prominent effect in the development of cardiovascular and cerebrovascular complications, but also platelet-derived growth factors produced by platelet aggregation have an important role in promoting the development of primary diseases of cardiovascular and cerebrovascular diseases.

Existing Chinese medicines are not able to resist thrombosis, and most of them are not effective.

The present invention unexpectedly finds that the existing product, ginseng capsule or other dosage form prepared from the same has a good antithrombotic effect. To this end, the present invention provides an antithrombotic preparation using red ginseng, chuanxiong and cassia twig. drug.

Summary of the invention:

The invention provides a traditional Chinese medicine preparation, which is prepared by processing Chinese traditional medicine red ginseng, Chuanxiong and cassia twig. The present invention also provides for the preparation of an antithrombotic drug using the traditional Chinese medicine preparation of the present invention.

The formulation of the traditional Chinese medicine preparation of the invention has the following composition:

Red ginseng l-1000g, Chuanxiong l-1000g, cassia twig l-1000g

Preferably - red ginseng 200-400g, Chuanxiong 250_750g, cassia twig 100_300g

Most preferred is:

Red Ginseng 300g, Chuanxiong 500g, Guizhi 200g

In the above composition, the weight is calculated based on the crude drug, and the above composition can be made into 1000 pharmaceutical preparations, and the 1000 doses refer to the finished pharmaceutical preparations, such as 1000 capsules, 1000 tablets, granules 1000. Gram, oral liquid 1000ml, etc.

The above composition, if in grams, can be made into 1000 doses of the preparation, such as tablets, made into 1000 tablets, each dose can be 1-100 tablets, a total of 1-1000 times. For example, as a granule, make 1-1000 bags, take 1-100 bags each time, and take 1-1000 times in total.

The above composition is based on the weight ratio, and can be increased or decreased according to the corresponding proportion during production. For example, mass production can be in kilograms or in tons, and small-scale production can also be in milligrams. It can be increased or decreased, but the ratio of the weight ratio of the raw medicinal materials between the components does not change.

The ratio of the above weight ratios is scientifically screened, for special patients, such as severe or mild, fat For fat or small patients, the proportion of the composition can be adjusted accordingly, increasing or decreasing by no more than 100%, and the efficacy is unchanged.

The single-flavored traditional Chinese medicines in the above composition, such as monarch, medicine and adjuvant, can also be replaced by appropriate Chinese medicines with the same medicinal properties, and the traditional Chinese medicine preparations after replacement have the same drug action.

The traditional Chinese medicine preparation of the present invention is prepared by extracting or otherwise processing the traditional Chinese medicine raw material composed of the above formula to prepare a pharmaceutically active substance, and then using the substance as a raw material, if necessary, adding a pharmaceutically acceptable carrier, according to the routine of preparation Made of technology. The active substance may be obtained by separately extracting a traditional Chinese medicine raw material, or may be obtained by jointly extracting a traditional Chinese medicine raw material, or may be obtained by other methods, such as: by pulverizing, pressing, calcining, grinding, sieving, seepage, extraction, water extraction , alcohol extraction, ester extraction, ketone extraction, chromatography, etc., these active substances may be in the form of extracts, which may be dry extracts or flow extracts, depending on the needs of the preparation, different concentrations are determined. .

The pharmaceutically active substance in the traditional Chinese medicine preparation of the present invention, the weight percentage thereof in the preparation may be

0. 1-99. 9%, the remainder being a pharmaceutically acceptable carrier. The pharmaceutical preparation of the present invention is in the form of a unit dosage form, which means a unit of the preparation, such as each tablet of the tablet, each capsule of the capsule, each bottle of the oral solution, granules per bag, and the like.

The traditional Chinese medicine preparation of the present invention may be any pharmaceutically acceptable dosage form, and the preparation forms include: tablets, sugar-coated tablets, film-coated tablets, enteric coated tablets, capsules, hard capsules, soft capsules, oral liquids, Oral preparation, granules, granules, pills, pills, powders, ointments, dans, suspensions, powders, solutions, injections, suppositories, ointments, plasters, creams, sprays, drops, stickers Agent. The preparation of the present invention is preferably an oral dosage form such as a capsule, a tablet, an oral solution, a granule, a pill, a powder, an agent, a paste or the like. Most preferred is a capsule, i.e., a ginseng capsule of the present invention.

The traditional Chinese medicine preparation of the present invention, the preparation for oral administration may contain common excipients such as a binder, a filler, a diluent, a compressed tablet, a lubricant, a disintegrant, a coloring agent, a flavoring agent and a wetting agent. , The tablets can be coated if necessary.

Suitable fillers include cellulose, mannitol, lactose and other similar fillers. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycolate. Suitable lubricants include, for example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulfate.

The solid oral composition can be prepared by a usual method such as mixing, filling, tableting or the like. Repeated mixing allows the active material to be distributed throughout those compositions that use large amounts of filler. The oral liquid preparation may be in the form of, for example, an aqueous or oily suspension, solution, emulsion, syrup or elixir, or may be a dry product which may be formulated with water or other suitable carrier before use. Such liquid preparations may contain conventional additives such as suspending agents such as sorbitol, syrup, methylcellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate or hydrogenated edible fats. Emulsifiers such as lecithin, sorbitan monooleate or gum arabic; non-aqueous carriers (which may include edible oils), such as almond oil, fractionated coconut oil, oily esters of esters such as glycerol, propylene glycol or ethanol; The agent, for example, p-hydroxybenzyl or propylparaben or sorbic acid, and if desired, may contain conventional flavoring or coloring agents.

For injection, the liquid unit dosage form prepared contains the active substance of the invention and a sterile vehicle. This compound can be suspended or dissolved depending on the carrier and concentration. The solution is usually prepared by dissolving the active substance in a carrier, sterilizing it by filtration before filling it into a suitable vial or ampoule, and then sealing. Excipients such as a local anesthetic, preservative and buffer may also be dissolved in such a carrier. To increase its stability, the composition can be frozen after filling the vial and the water removed under vacuum.

The traditional Chinese medicine preparation of the present invention can be selectively added to a suitable pharmaceutically acceptable carrier when prepared as a medicament, the pharmaceutically acceptable carrier being selected from the group consisting of: mannitol, sorbitol, sodium metabisulfite, sodium hydrogen sulfite, thio Sodium sulfate, cysteine hydrochloride, thioglycolic acid, methionine, vitamins (:, EDTA disodium, EDTA calcium sodium, monovalent alkali metal carbonate, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulfuric acid , phosphoric acid, amino acid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivatives, cellulose and their derivatives , alginate, gelatin, polyvinylpyrrolidone, glycerin, earth temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, polyethylene glycol, cyclodextrin, beta-cyclodextrin, phospholipids, Kaolin, talc, calcium stearate, magnesium stearate, etc.

The preparation of the invention is used according to the condition of the patient at the time of use, and can be taken two to four times a day, each time.

1-20 doses, such as: 1-20 bags or tablets or tablets.

The traditional Chinese medicine preparation of the present invention can be produced by the following method.

Take red ginseng, pulverize into fine powder, spare; the remaining red ginseng is pulverized into coarse powder, and the percolation method under the extract of extract and extract (Chinese Pharmacopoeia 2000 edition, Appendix I 0), using ethanol as solvent Seepage, collect the seepage solution, reserve; Chuanxiong, Guizhi add water to extract volatile oil, collect volatile oil, reserve; distillate filtered, the filtrate is reserved; the dregs and the above red ginseng residue are decoctioned twice, filtered, filtrate Consolidate, concentrate, let cool, Add ethanol, place, filter, and combine the filtrate with red ginseng osmosis solution, recover ethanol and concentrate to thick paste, add red ginseng powder, mix with hook, dry, pulverize into fine powder. The volatile oil is adsorbed by the remaining red ginseng fine powder, mixed and hooked, and then mixed with the above fine powder to obtain the pharmaceutically active substance of the present invention. The pharmaceutically active substance is mixed with a pharmaceutically acceptable carrier, and a pharmaceutical preparation of the invention can be prepared by a conventional technique of formulation.

The pharmaceutical preparation of the present invention is particularly suitable and applied to antithrombotic formation. For this reason, the present invention provides an application for preparing an antithrombotic drug using the pharmaceutical preparation of the present invention.

The application of the present invention has been unexpectedly discovered by conducting a new pharmacodynamic study on the drug of the present invention, particularly Shenui Capsule, and has achieved unexpected results compared with the prior art. The following are experimental research data. Experimental study on anti-thrombosis of Shenui Capsule

Experimental material

1. 1 Experimental drug: Yudan ® Shenui Capsule, clinical dosage: 3-4 capsules each time (each content is 0. 3g), orally 3 times a day. Provided by Shanghai Yudan Pharmaceutical Co., Ltd., batch number: 20090801. Aspirin, clinical use: lOOmg / time / day orally. Product by Xinyi Pharmaceutical General Factory of Shanghai Pharmaceutical (Group) Co., Ltd., batch number: 090201. Coomassie Brilliant Blue G250, Beijing Dingguo Biotechnology Co., Ltd., batch number: 7AD10349. Bovine serum albumin, product of Huamei Bioengineering Co., Ltd., batch number: 0103.

1. 2 Experimental animals: SD rats, male, SPF grade, weighing 260_300g. Provided by the Experimental Animal Center of Shanghai University of Traditional Chinese Medicine, certificate number: SCXK (Shanghai) 2008-0016.

1. 3 Experimental equipment: UV-visible spectrophotometer, model Agilent 8453, manufactured by Agilent Technologies. Stainless iron micro compression spring, Shanghai Haiwei spring factory products, specifications 0. 8mm (inside diameter).

2 methods and steps

2. 1 drug formulation and usage:

Yudan ® Shenui Capsule: According to the body surface area, the amount of rats was converted into the amount of rats, high dose group L 8g / kg, medium dose group 0. 9g / kg, low dose group 0. 45g / kg. Weigh the required amount, add distilled water, and make a suspension of 1. 8g / ml, 0.9g / ml, 0. 45g / ml, respectively, 0. lml / 100g (body weight) by gastric administration. Aspirin: According to the body surface area, the clinical dose of lOOmg / day is converted into the amount of rats, 9mg / kg. Weigh the required amount, add distilled water, make a 9mg/ml suspension, and use 0.1 ml/100g (body weight) for gastric administration.

2. 2 experimental methods and steps:

References [7, 8], 90 SD rats, SPF grade, male, weight 260_300g. Balanced weight The machine was divided into 6 groups: 20 blank control groups, given the same amount of normal saline; Shenui capsule high dose group, middle dose group, low dose group, positive control group, Shengui capsule middle dose group and positive drug combination group, each Group 15 only. Each group of rats was intragastrically administered once a day for 7 consecutive days, 60 minutes after the last dose, 10% urethane 1100/100g intraperitoneal anesthesia, and the elevation was fixed on the operating table of the rat constant temperature (37 °C). Perform surgery. Bend the hair to the abdomen, cut the abdominal skin in the middle, and bluntly peel off the rectus abdominis and enter the abdominal cavity. A small iron micro-pressure spring was implanted in the direction of the renal vein in the caudal iliac vein of the tail vein to suppress hemostasis. Close the abdominal cavity. After 2 hours, open the abdominal cavity, take out the stainless iron micro-pressure spring and the thrombus together, wash gently with physiological saline, and absorb excess water. The compression spring and the thrombus were placed in 2 ml of an alkaline sodium carbonate solution (100 mmol/L sodium hydroxide, 2% sodium carbonate), and placed in a boiling water bath for 3 min. The protein content in the 100 μ ΐ sample was determined by the Coomassie brilliant blue method (Bradford method).

2. 3 Coomassie Brilliant Method (Bradford Method) Determination of protein concentration:

2. 3. 1 Reagents: (1) Standard protein solution, prepared with bovine serum albumin (BSA), a standard protein solution of L 0 mg/ml and 0.1 mg/ml. (2) Coomassie brilliant blue G-250 dye reagent: Weigh lOOmg Coomassie brilliant blue G-250, dissolved in 95% ethanol 50ml, then add 120ml of 85% phosphoric acid, diluted to 1 liter with water. 2. 3. 2 standard curve production and unknown sample measurement methods

(1) Take the test tubes as needed and divide them into two groups. A set of standard protein solutions with 1.0 mg/ml were added to each tube: 0 (for blank), 0. 005, 0. 01, 0. 02, 0. 03, 0. 04, 0. 05ml, then 0毫升。 Adding with 0. 05ml. The rest is left as an unknown sample. 0. 05ml sample solution per tube. Finally, add 2. 5 ml of Coomassie Brilliant G-250 Reagent to each tube and mix immediately on the vortex mixer after each tube.

(2) After the reagent was added for 5 minutes, the blank tube was adjusted to zero, and the light absorption value (A ₅₉₅ ) of each sample at 595 nm was measured on a spectrophotometer. (3) Using the standard protein amount (mg) as the abscissa, and using the absorbance value A ₅₉₅ as the ordinate, plotting, that is, a standard curve is obtained. From this standard curve, the protein content of the unknown sample is detected based on the measured A ₅₉₅ value of the unknown sample.

2. 4 Statistical analysis: The data indicates the degree of thrombosis by the standard deviation of the mean value of thrombus protein content, and the degree of thrombosis is high in patients with high protein content. Statistical significance was compared between groups using the t test.

3. Experimental results

3. 1 protein standard curve is shown in Figure 1. The phage value is 0. lmg. /ml to 0. 6mg / ml, the absorbance value rises quickly; from 0. 6mg / ml to 1. Omg / ml absorbance value rises again Slow down. Because the protein content in the normal animal thrombus is higher, and the drug inhibits the thrombus protein content of the thrombotic animal, the standard protein liquid control tube of the high and low concentrations is required for the actual determination of the protein content.

3. 2 The results of thrombus protein assay are shown in Figure 2. The results of statistical t-test showed that all the drug-treated groups including the positive drug group, the experimental drug high, medium and low dose groups and the unmedicated (blank) group were significantly different (P <0.01), indicating that the Shengui capsule has significant The inhibition of thrombosis. However, the difference between the medication groups was not significant, indicating that the high, medium and low doses of Shenui Capsule had reached their maximum intensity. The "Shen A group" in the medication group was the combination of Shenui Capsule and Aspirin. The antithrombotic effect was not significantly different from the aspirin group alone or the high, medium and low dose groups of Shenui Capsule. There is no significant synergy between aspirin and it has reached its maximum intensity of action.

4. Discussion

Chinese medicine believes that angina pectoris is a category of chest sputum, and its pathogenesis stems from the slight suffocation of the upper Jiaoyang. "Golden 匮 · · 痹痹痹痹痹短短短短短短短短短》》》曰曰曰曰曰曰曰曰曰曰曰曰曰曰曰曰曰曰曰曰曰曰曰曰曰曰曰曰曰曰曰曰曰曰The imaginary yang is on the coke, so the chest is heartache, and the sinus is also ". In the Shenui Capsule, the red ginseng and the qi, the Guizhi Wenyang, and the Chuanxiong Tongmai are used for the chest sputum with yang deficiency and qi deficiency and blood stasis. Pharmacological studies reported in related literature mostly involve the mechanism of cardiac dysfunction. For example, the mechanism of action of Shengui Capsule in treating cardiac dysfunction is related to its intervention in myocardial remodeling and inhibition of cardiomyocyte apoptosis, and it also reduces plasma endothelin (ET). , angiotensin i Arig ll) level and other effects. However, according to the research results of traditional Chinese medicine pharmacology, the role of Shengui Capsules in forming drugs is not limited to this.

Modern pharmacological studies have shown that intravenous injection of 50mg/kg and 70mg/kg rabbits in the panaxadiol group inhibits platelet aggregation. The ginseng root dose of 60 mg/kg can significantly inhibit the thrombosis of blood stasis rats. Many studies have confirmed the inhibitory effect of ginseng or ginseng saponin on platelet aggregation, and believe that its mechanism of action and increase platelet cAMPCa ⁺⁺ antagonism and block PG metabolism (inhibition of cyclooxygenase and TXA2 synthetase, reduce TXA2, PGA2 production) Related to the role. Intraperitoneal injection of Guizhi injection can relieve red blood cell and platelet aggregation in rabbit experimental limb snoring model and improve tissue blood circulation. Cinnamaldehyde inhibits platelet aggregation in vitro. Chuanxiong and Chuanxiong have significant inhibitory effects on rabbit and human platelet aggregation induced by ADP, collagen and thrombin in vitro, and rapidly disaggregate the aggregated platelets. Chuanxiong can inhibit platelet aggregation in allergic asthma guinea pigs and sepsis rabbits. Cardiovascular and cerebrovascular patients can take red blood cells and platelet surface after taking Chuanxiong The charge increases and the aggregation decreases. The mechanism by which Chuanxiong inhibits platelet aggregation may be related to inhibition of intracellular Ca ⁺⁺ release, affecting the balance between TXA2/PGI2, and replacement of platelet membrane Ca ^{++ to} increase membrane negative charge, and may also be related to (Chuangchuan and Chuanxiong injections). ) Increased (mouse plasma and rabbit platelet suspension) effects on cAMP levels.

The results of this trial showed that the three groups can still significantly inhibit thrombosis. Moreover, its maximum inhibitory effect on thrombus formation is equivalent to the usual clinical dose of aspirin. Therefore, it is advisable to use Shengui capsule alone for antithrombotic therapy in clinical application. In addition, there was no obvious synergistic enhancement effect between Shengui Capsule and aspirin, indicating that it did not inhibit the safety hazard caused by platelet aggregation function when combined with aspirin. Aspirin is a commonly used drug for preventing thrombosis in clinical practice. Therefore, if the patient takes the Shengui capsule while taking the aspirin for preventing thrombosis, the usual amount is also safe.

By inhibiting the formation of intravascular thrombus and preventing some pathological links in the development of vascular lesions, Shenui Capsule can not only improve the coronary blood supply of the heart, but also can be used for the prevention of peripheral blood vessels and cerebrovascular diseases.

references:

[1] Yin Huijun, Jiang Yuerong, Liu Ying, Wang Chenglong, Guo Yan, Study on the effect of Shengui Capsule on cardiac function after myocardial infarction in rats, Shanghai Medical Journal [J] , 2005, 26 ( 10 ) : 447-448.

[2] Li Zongxi, Li Wenchao, Li Wenquan, Dong Yuxiu, The effect of Shengui Capsule on hemodynamics in dogs, Journal of Henan College of Traditional Chinese Medicine [J], 2003, 18 ( 2 ) : 22-28.

[3] Li Zongqi, Su Runtang, Pharmacological Research of Shenui Capsule, Journal of Beijing University of Traditional Chinese Medicine [J] , 2003, 26 (4) : 56-58.

[4] Yan Xiushuang, Li Yunfu, Dang Yanping, Shen Gui Capsule for the treatment of severe congestive heart failure: Chinese pharmacy [J], 2008, 19 ( 30 ) : 2391-2392.

[5] Liu Yu, Sun Fangyi, Shen Gui Capsule for the treatment of 113 cases of unstable angina pectoris of coronary heart disease, Chinese and Western medicine combined with cardiovascular and cerebrovascular disease [J], 2007, 5 ( 9 ) : 879.

[6] Li Zheng, Huang Ping, Zhang Ju, Li Zongxi, Huang Yuxiu, Shen Gui Capsule for the treatment of coronary heart disease with angina pectoris, Chinese Journal of Medicine [J], 2000, 15 (4): 35-36.

[7] Kumada T, Ishihara M, Ogawa H, Abiko Y (1980) , Experimental model of venous thrombosis in rats and effect of some agents, Thrombosis Res. , 18 : 189-203.

[8] Just M, Schonaf inger K (1991), Antithrombotic prop erties of a novel sydnonimine derivative, J Cardiovasc Pharmacol 17 (suppl 3): S121-S126.

[9] Yin Huijun, Jiang Yuerong, Liu Ying, Zhang Ying Shen Gui Capsule on the effects of ET and Ang II in rats with myocardial infarction after cardiac insufficiency, Chinese Journal of Integrated Traditional and Western Cardiology, 2007, 2 ( 6 ) : 336- 337.

[10] Chinese Materia Medica, Shanghai Science and Technology Press, 1999, First Edition, Volume 5: 812.

[11] Chinese Materia Medica, Shanghai Science and Technology Press, 1999, First Edition, Volume 3: 42-43.

[12] Chinese Materia Medica, Shanghai Science and Technology Press, 1999, First Edition, Volume 5: 978.

BRIEF DESCRIPTION OF THE DRAWINGS:

Figure 1 Coomassie brilliant blue determination of protein content standard curve

Figure 2 Thrombus protein content determination results

detailed description:

The invention is further illustrated by the following examples, which are not intended to limit the invention.

Example 1

Preparation of medicinal substances of Shengui Capsule:

Recipe:

Red Ginseng 300g, Chuanxiong 500g, Guizhi 200g

Take red ginseng, pulverize into fine powder, spare; the remaining red ginseng is pulverized into coarse powder, and the percolation method under the extract of extract and extract (Chinese Pharmacopoeia 2000 edition, Appendix I 0), using ethanol as solvent Seepage, collect the seepage solution, reserve; Chuanxiong, Guizhi add water to extract volatile oil, collect volatile oil, reserve; distillate filtered, the filtrate is reserved; the dregs and the above red ginseng residue are decoctioned twice, filtered, filtrate Combine, concentrate, let cool, add ethanol, place, filter, and combine the filtrate with red ginseng osmosis solution, recover ethanol and concentrate to thick paste, add red ginseng powder, mix with hook, dry, pulverize into fine powder. The volatile oil is adsorbed by the remaining red ginseng fine powder, mixed and hooked, and then mixed with the above fine powder to obtain the pharmaceutically active substance of the ginseng capsule of the present invention. Example 2

Preparation of capsules (Shengui capsules),

The pharmaceutically active substance of Example 1 was added with an appropriate amount of starch, mixed, and granulated, and 1000 capsules were obtained. Example 3

Preparation of tablets,

The pharmaceutically active substance of Example 1 was added with an appropriate amount of starch, mixed, and granulated, and compressed into 1000 pieces to obtain. Example 4

Preparation of granules,

The pharmaceutically active substance of Example 1 was added with an appropriate amount of starch, sucrose, and a hook to make 1000 g, and packaged into 2 g/bag, which was obtained. Example 5

Preparation of pharmaceutically active substances:

Recipe:

Red Ginseng 200g, Chuanxiong 250g, Guizhi 100g

Take red ginseng, pulverize into fine powder, spare; the remaining red ginseng is pulverized into coarse powder, and the percolation method under the extract of extract and extract (Chinese Pharmacopoeia 2000 edition, Appendix I 0), using ethanol as solvent Seepage, collect the seepage solution, reserve; Chuanxiong, Guizhi add water to extract volatile oil, collect volatile oil, reserve; distillate filtered, the filtrate is reserved; the dregs and the above red ginseng residue are decoctioned twice, filtered, filtrate Combine, concentrate, let cool, add ethanol, place, filter, and combine the filtrate with red ginseng osmosis solution, recover ethanol and concentrate to thick paste, add red ginseng powder, mix with hook, dry, pulverize into fine powder. The volatile oil is adsorbed by the remaining red ginseng fine powder, mixed and hooked, and then mixed with the above fine powder to obtain the pharmaceutically active substance of the present invention. Example 6

Preparation of pharmaceutically active substances:

Recipe:

Red Ginseng 400g, Chuanxiong 750g, Guizhi 300g

Take red ginseng, pulverize into fine powder, spare; the remaining red ginseng is pulverized into coarse powder, and the percolation method under the extract of extract and extract (Chinese Pharmacopoeia 2000 edition, Appendix I 0), using ethanol as solvent Seepage, collecting percolate, and standby; extracting volatile oil from Chuanxiong and Guizhi by adding water, collecting volatile oil, and storing; distillate filtered, The filtrate is reserved; the dregs and the above red ginseng slag are boiled twice with water, filtered, the filtrate is combined, concentrated, allowed to cool, added with ethanol, placed, filtered, and the filtrate is combined with the red ginseng osmosis solution, and the ethanol is recovered and concentrated. Thick paste, add red ginseng powder, mix with hook, dry, pulverize into fine powder. The volatile oil is adsorbed by the remaining red ginseng fine powder, mixed, and then mixed with the above fine powder to obtain the pharmaceutically active substance of the present invention.

Claims

claims

1. Application of pharmaceutical preparations prepared from traditional Chinese medicines red ginseng, chuanxiong and cassia twig in the preparation of anti-thrombotic drugs.

2. The application according to claim 1, characterized in that the application is to inhibit the formation of thrombus.

3. The application according to claim 1, characterized in that the application is used for the prevention and treatment of peripheral vascular and cerebrovascular diseases.

4. The application according to claim 1, characterized in that the application is for the treatment of cerebral infarction.

5. The application according to claim 1, characterized in that the application is to improve the coronary blood supply of the heart.

6. The application according to claim 1, characterized in that the application is for the treatment of myocardial infarction.

7. Application according to claim 1, characterized in that the formula of the medicine is as follows: red ginseng 1-1000g, Ligusticum chuanxiong 1-1000g, cassia twig 1-1000go

8. Application according to claim 1, characterized in that the formula of the medicine is as follows: red ginseng 200-400g, Ligusticum chuanxiong 250-750g, cassia twig 100-300g.

9. Application according to claim 1, characterized in that the formula of the medicine is as follows: 300g red ginseng, 500g chuanxiong, and 200g cassia twig.

10. Application according to claim 1, characterized in that the pharmaceutical preparation method is as follows:

Red ginseng 300g, Chuanxiong 500g, Guizhi 200g

Take the red ginseng and crush it into fine powder and set aside; crush the remaining red ginseng into coarse powder and follow the percolation method under Appendix 10 of the Chinese Pharmacopoeia 2000 edition, using ethanol as the solvent. , collect the leachate, and set it aside; add water to distill Ligusticum Chuanxiong and Guizhi to extract the volatile oil, collect the volatile oil, and set it aside; filter the distillate, and set the filtrate for set use; decoct the medicinal residue and the above-mentioned red ginseng medicinal residue twice with water, filter, and combine the filtrate. Concentrate, let cool, add ethanol, let stand, filter, combine the filtrate and red ginseng leachate, recover the ethanol and concentrate to a thick paste, add red ginseng fine powder, mix, dry and pulverize into fine powder. The volatile oil is adsorbed with the remaining fine red ginseng powder, mixed, then mixed with the above fine powder, added with an appropriate amount of starch, mixed, put into capsules, and granulated to obtain.